Jump to main content
Jump to site search

Issue 36, 2018
Previous Article Next Article

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

Author affiliations

Abstract

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components at the blood–brain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD.

Graphical abstract: Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

Back to tab navigation

Publication details

The article was received on 20 May 2018, accepted on 24 Aug 2018 and first published on 27 Aug 2018


Article type: Review Article
DOI: 10.1039/C8NR04073G
Citation: Nanoscale, 2018,10, 16962-16983
  •   Request permissions

    Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

    N. Poovaiah, Z. Davoudi, H. Peng, B. Schlichtmann, S. Mallapragada, B. Narasimhan and Q. Wang, Nanoscale, 2018, 10, 16962
    DOI: 10.1039/C8NR04073G

Search articles by author

Spotlight

Advertisements